Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)

NCT06045754 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06045754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06045754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Recruiting
Start date
April 18, 2024
Completion date
June 28, 2027
Enrollment
50 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease